Stocks Pfizer Inc

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks looks set to start the last day of 2009 with a slight gain, although volume could be thin with many investors looking to pop the champagne corks early.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks looks set to start the last day of 2009 with a slight gain, although volume could be thin with many investors looking to pop the champagne corks early.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks erased their losses Wednesday — and the Dow and Nasdaq pulled off a gain — after a better-than-expected report on Midwest manufacturing.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks pared their losses Wednesday after a better-than-expected report on Midwest manufacturing.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stock index futures pointed to a lower start Wednesday, following a day where the market snapped its winning streak, trading in a very small range.

  • Best & Worst of the Decade

    Following the sizzling 1990s (the markets’ best decade ever), stocks have had a disappointing decade overall, fizzling in the 2000s.  Here are the best and worst of the Dow.

  • dogs_ofthe_dow.jpg

    A popular investment strategy suggests buying the ten Dow Jones Industrial Average components with the highest yielding dividends. Here is the list going into 2010.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks closed higher as a holiday rally got a further push from big technology, banks and commodities, though most investors took Christmas Eve off.

  • Winterizing Your Portfolio - A CNBC Special Report

    Futures mostly shrugged off news that weekly unemployment claims hit their lowest level in 15 months, but stocks were still poised for a gain in a holiday-shortened session Thursday.

  • pills_prescription_200.jpg

    I can’t wait until this drug rises to the level where it gets on Joe Kernen’s radar screen because, boy, is he gonna have a good time (not just with the drug perhaps, but mostly with talking on TV about it.) A little TMI, I know, but that’s Joe.

  • These companies offer great cash payouts and the potential for upside.

  • Dividend investing is considered a sound course in times of market turmoil. So what are the best dividend plays for investors in 2010? Dan Genter, president, CEO and CIO of RNC Genter Capital Management, shared his stock picks.

  • nicorette_ad_200.jpg

    It's New Year's resolution time, so it's no surprise to see a sudden increase in commercials and ads for stop-smoking products. Pfizer's been heavily pushing its challenged Chantix and the other day I saw a commercial for GlaxoSmithKline's Nicorette that nearly made my jaw drop.

  • When rumors spread about takeovers, it's routine to see the stock of the acquiring company take a hit, but that's not always the case.

  • With all the chatter about moving away from equities into "safer" instruments like bonds or CDs, Cramer is giving viewers a reality check.

  • The Federal Reserve's pledge to keep interest rates at near zero for an extended period means US markets will continue to rise in early 2010, but asset bubbles and a shaky world economy will cause some investors to pull out of emerging markets, said Eric Ross of Watch Harbor Asset Management.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks advanced Monday, with the Nasdaq closing at a new 15-month high, after upgrades on Alcoa and Intel and as the Senate health-care bill advanced.

  • alzheimers1_200.jpg

    This morning biopharma P & A reached critical mass. In a rare, holiday-week confluence, four major pharmaceutical companies announced partnership deals and one announced a nearly $2-billion acquisition. All of the partnerships are on drugs that are still in the testing stage. If they were to all come to fruition, which in the risky business of drug development is highly unlikely, the new partnerships could collectively be worth billions of dollars over time.

  • Healthcare coverage and the hastle of forms

    There is nothing in this bill that changes our views at Soleil regarding the health care stocks we have been recommending.

  • Cramer makes the call on viewers' favorite stocks.